BRIEF-Lantheus Announces Three-Month Extension Of PDUFA Date For LNTH-2501

Reuters
9 hours ago
BRIEF-Lantheus Announces Three-Month Extension Of PDUFA Date For LNTH-2501

March 17 (Reuters) - Lantheus Holdings Inc LNTH.O:

  • LANTHEUS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR LNTH-2501 (GA 68 EDOTREOTIDE), A PET DIAGNOSTIC IMAGING KIT TARGETING SOMATOSTATIN RECEPTOR-POSITIVE (SSTR+) NEUROENDOCRINE TUMORS $(NETS)$

  • LANTHEUS HOLDINGS INC - STANDARD REVIEW EXTENSION FOR LNTH-2501 NOT RELATED TO EFFICACY OR SAFETY DATA

  • LANTHEUS HOLDINGS INC - FDA EXTENDS REVIEW OF LNTH-2501 NDA TO JUNE 29, 2026

  • LANTHEUS HOLDINGS INC - FDA EXTENDS PDUFA GOAL DATE FOR LNTH-2501 TO JUNE 29, 2026

Source text: ID:nGNXbZfXpL

Further company coverage: LNTH.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10